176 related articles for article (PubMed ID: 22995087)
21. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
[TBL] [Abstract][Full Text] [Related]
22. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
[TBL] [Abstract][Full Text] [Related]
23. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial.
Kang WC; Ahn T; Lee K; Han SH; Shin EK; Jeong MH; Yoon JH; Park JS; Bae JH; Hur SH; Rha SW; Oh SK; Kim DI; Jang Y; Choi JW; Kim BO
EuroIntervention; 2011 Dec; 7(8):936-43. PubMed ID: 21959255
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
Zhang YJ; Zhao YL; Xu B; Han YL; Li B; Liu Q; Su X; Pang S; Lu SZ; Guo XF; Yang YJ
Chin Med J (Engl); 2015 Mar; 128(6):714-20. PubMed ID: 25758261
[TBL] [Abstract][Full Text] [Related]
25. Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials.
Bezenek S; Hermiller J; Lansky A; Yaqub M; Hattori K; Cao S; Sood P; Sudhir K
J Interv Cardiol; 2011 Aug; 24(4):326-41. PubMed ID: 21443551
[TBL] [Abstract][Full Text] [Related]
26. Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.
Dangas GD; Claessen BE; Mehran R; Xu K; Stone GW
EuroIntervention; 2013 Jan; 8(9):1033-9. PubMed ID: 23339809
[TBL] [Abstract][Full Text] [Related]
27. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.
Park KW; Chae IH; Lim DS; Han KR; Yang HM; Lee HY; Kang HJ; Koo BK; Ahn T; Yoon JH; Jeong MH; Hong TJ; Chung WY; Jo SH; Choi YJ; Hur SH; Kwon HM; Jeon DW; Kim BO; Park SH; Lee NH; Jeon HK; Gwon HC; Jang YS; Kim HS
J Am Coll Cardiol; 2011 Oct; 58(18):1844-54. PubMed ID: 22018294
[TBL] [Abstract][Full Text] [Related]
28. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.
Natsuaki M; Morimoto T; Yamamoto E; Shiomi H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Igarashi K; Tanabe K; Kozuma K; Kimura T
Cardiovasc Interv Ther; 2016 Jul; 31(3):196-209. PubMed ID: 26518420
[TBL] [Abstract][Full Text] [Related]
29. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
30. Six-month angiographic and one-year clinical outcomes of polymer free paclitaxel-eluting stent in patients with ST-segment elevation myocardial infarction: a comparison with permanent polymer sirolimus-eluting stent.
Dang Q; Li YJ; Gao L; Jin Z; Gou LX
Chin Med J (Engl); 2012 Oct; 125(19):3393-7. PubMed ID: 23044294
[TBL] [Abstract][Full Text] [Related]
31. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial.
Karjalainen PP; Niemelä M; Airaksinen JK; Rivero-Crespo F; Romppanen H; Sia J; Lalmand J; de Bruyne B; Debelder A; Carlier M; Nammas W; Ylitalo A; Hess OM;
EuroIntervention; 2012 Jul; 8(3):306-15. PubMed ID: 22829506
[TBL] [Abstract][Full Text] [Related]
33. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
[TBL] [Abstract][Full Text] [Related]
34. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.
Wenaweser P; Daemen J; Zwahlen M; van Domburg R; Jüni P; Vaina S; Hellige G; Tsuchida K; Morger C; Boersma E; Kukreja N; Meier B; Serruys PW; Windecker S
J Am Coll Cardiol; 2008 Sep; 52(14):1134-40. PubMed ID: 18804739
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of everolimus-eluting stents versus sirolimus-eluting stents in women.
Badr S; Barbash IM; Dvir D; Torguson R; Xue Z; Kitabata H; Sardi G; Loh JP; Pichard AD; Waksman R
Am J Cardiol; 2013 Jan; 111(1):21-5. PubMed ID: 23040594
[TBL] [Abstract][Full Text] [Related]
36. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
[TBL] [Abstract][Full Text] [Related]
37. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
Stone GW; Rizvi A; Sudhir K; Newman W; Applegate RJ; Cannon LA; Maddux JT; Cutlip DE; Simonton CA; Sood P; Kereiakes DJ;
J Am Coll Cardiol; 2011 Jun; 58(1):19-25. PubMed ID: 21514084
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.
Park KW; Lee JM; Kang SH; Ahn HS; Yang HM; Lee HY; Kang HJ; Koo BK; Cho J; Gwon HC; Lee SY; Chae IH; Youn TJ; Chae JK; Han KR; Yu CW; Kim HS
J Am Coll Cardiol; 2013 Feb; 61(5):536-44. PubMed ID: 23273394
[TBL] [Abstract][Full Text] [Related]
39. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
Qian J; Chen Z; Ma J; Ge J
Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
[TBL] [Abstract][Full Text] [Related]
40. Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.
Mahmoudi M; Delhaye C; Wakabayashi K; Ben-Dor I; Gonzalez MA; Maluenda G; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Am J Cardiol; 2011 Jun; 107(12):1757-62. PubMed ID: 21497782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
